Zenas BioPharma Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the fireside chat with our next company, Zenas BioPharma, and we have a CEO, Lonnie Moulder, here. Lonnie will give us a quick overview and then sit down with me for the chat.
Lonnie. Thank you, Roger. It's great to be here.
We appreciate you all attending, hearing a little bit about Zenas today, and we'll be making some forward-looking statements, so I refer you to our SEC filings. This is the pipeline, and I think many of you are familiar with it. We have quite a bit going on across our future rheumatology and neuroimmunology franchises. Today, we'll focus mostly in on obexelimab, IgG4-related disease, which is an indication that we're pursuing with a BLA under review, a PDUFA date of May 27th next year, and an MAA also under review. We'll talk a little bit about the SunStone phase IIb lupus or SLE trial. I think Roger has some interest in discussing that. Then we'll probably skip to ZB021 because we have some near-term data for our oral IL-17 inhibitor that I think quite a few people have interest in.
So if we look at IgG4-RD, first of all, as the first launch indication for obexelimab, potentially by the middle of next year, we have a lot of activities underway that we'll discuss more in preparing for that launch. But I would say critical to this, so that you understand our positioning, is we believe this drug has the right balance of efficacy and safety. With its unique mechanism of action, it provides a lot of flexibility to clinicians in treating patients that are older and have a lot of comorbidities, and it's very convenient with a subcutaneous administration where patients can take this at home to manage their disease, which is a chronic disease. This is a disease where patients need to take the medication for years, because if they flare, not being controlled with medication, if they flare, it leads to organ damage over time and fibrosis.
The initiatives right now are really to prepare the marketplace. We've had our medical science liaisons in the field for scientific exchange purposes with key opinion leaders, investigators, and others, primarily in the rheumatology community. We just returned from the American College of Rheumatology meeting last week, where we had a great deal of exchange and market research ongoing that's really solidified our overall launch strategy. From a deployment standpoint, it's important that we target with our resources those clinicians that do most of the prescribing in this field, and we've identified through claims data that there are just over 7,000 healthcare professionals that should be targeted by our sales force and our other resources. The accounts that those clinicians practice in overall manage just over 90% of all IgG4-RD patients, and the requirement is that we deploy 45 sales representatives.
So to date, we have our marketing team in place, our market research team in place, market access team in place, medical science liaisons. We will supplement that, of course, with what we call strategic engagement personnel, nurse educators, and then the sales force, which will be hired approximately one quarter prior to launch, as listed here. So, at the ACR meeting, we followed up on the recent IgG4-RD symposium where new data was put forward. As you may recall, obexelimab was the subject of a large randomized phase III trial that we call INDIGO, and that was a 52-week trial. Following the randomized control period of that trial is a three-year open-label extension. So, at the symposium, and then following up at the ACR meeting, data were presented that looked at the next 52-week probability of flare protection, flare protection of approximately 90%.
So we are quite pleased to see that sustainability over time and a side effect profile that is similar to the 52-week period where the degree of serious adverse events and grade 3 infections was actually no greater than the placebo arm. So, a great data set. In addition, many of you know that there is a vaccine sub-study as part of that open-label extension study, and that is where certain clinical sites have the ability to pause obexelimab use, administer a vaccine, and it is either COVID, flu, or both, then restart after two weeks on obexelimab and assess antibody titers to flu and COVID. Noted here is the number of patients that attained the benchmark level of immunity that one would want to see. That is the flexibility I mentioned earlier with this molecule as an inhibitor instead of a depleter of B cells.
So that brought in a lot of attention with our team out at ACR. Moving briefly to obexelimab in SLE, which we will talk about in just a moment. As you know, there was a phase II-A study conducted by Xencor a number of years ago, and that phase II-A study gave us the proof of concept that this drug could be meaningful in lupus. In addition, the work that they did with deep sequencing showed a gene pattern or a set of patterns that could predict even greater responsiveness to the drug. So we are conducting the phase II-B SunStone trial in SLE, and we are looking at that biomarker strategy where it is an all-comer population, but all patients will be assessed for how the biomarker performs.
The data that we will be releasing later this quarter will be the MITT population, the BICLA measurement as the primary endpoint, the MITT population for SRI-4, really looking at both of those to determine what might make sense to bring into a phase III program. Then we will also look at the biomarker positive population for each of those two key endpoints, and then think about what type of phase III could be designed. Should it be an all-comer trial? Would it be an all-comer trial where we first test for biomarker in a hierarchy and then the overall population? Or will it be a biomarker-only driven trial where we select for biomarker-positive patients to begin with? All that will be decided once we have the results of the phase II-B study in a few weeks. I will wrap up here with our oral IL-17 inhibitor.
I think many of you are well aware of the first interleukin oral inhibitor out there. J&J is marketing an oral IL-17 peptide. As you know, IL-23 peptide, as you probably know, IL-17 has a lot of relevance in diseases that overlap with IL-23, but in particular, in rheumatic diseases, more bone as opposed to skin-oriented. We, as a company that are building a rheumatology franchise, are quite interested in advancing our IL-17 inhibitor into rheumatic diseases. First step, though, is how does this profile look relative to agents that are already approved, those being biologics? You've heard this before. Is there an opportunity to take a molecule that's smaller in size and might have greater penetration to the diseased tissue, whether that's skin layers or, as you see on the left, entheses, the synovial area?
What we conducted here was a mini pig study where we actually look at how do the target tissues pick up the drug compared to the drug concentration in plasma. On the left axis, it's really a ratio in percentages. You can see that across all those tissues, the concentration is actually greater than in the plasma. I think that amplifies what's on the right, what a small molecule looks like, ZB021, in size compared to whether it's a peptide inhibitor, an antibody, or a full IgG monoclonal antibody. We think there's an opportunity here to leverage the size of this molecule into certain diseases. For us, the way we've designed our current study is to look at those characteristics you want to in phase I. What is the exposure, the exposure relative to IC50 and IC90, safety, tolerability?
Can we make this happen with once-daily dosing? We've already indicated we believe we can, but we'll have the specifics on some of this here in a few weeks. Then think about where we go next, which is most likely a rheumatic disease as phase II proof of concept to then set up moving into phase III. With that, I'll sit down and join Roger over here.
Thank you, Lon. All right, so you have a couple things in the pipeline. Maybe we'll focus on the obexelimab in IgG4 first, maybe a little bit of SLE, and certainly we're going to talk about IL-17 as well. For the SLE, understanding it's under review, PDUFA date next year, early next year. How much you can tell us about the regulatory process, mid-cycle review, et cetera, and also the CMC side, how ready that is, understanding it's a single supplier?
Yeah. So for IgG4-related disease with obexelimab, obviously under active review, and some of this is statutory. There's a mid-cycle review, there's a late-cycle review, there's a time when label negotiations begin. We don't comment on specifics of regulatory review, but we're already through the mid-cycle review. You can do the calculation. It's the type of interaction that tells us that regardless of what you hear from the outside about the FDA, we know the rheumatology team is working hard. We have a lot of interaction. Along the way, there'll be manufacturing site inspections, drug supply, drug product, or drug substance, drug product, clinical sites, and the company itself is inspected. That's just normal process. All of that is going as expected. As I mentioned before, the PDUFA date is May 27th.
Okay. As far as manufacturing CMC overall, we have a supply chain obviously in place for our current formulation, which we would anticipate for launch, which is a prefilled syringe.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
